Denali Therapeutics (NASDAQ:DNLI - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $3.24 million for the quarter.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. On average, analysts expect Denali Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Denali Therapeutics Stock Performance
Shares of NASDAQ:DNLI traded up $0.38 on Friday, hitting $16.44. 1,118,564 shares of the company were exchanged, compared to its average volume of 1,087,313. The company's 50 day moving average price is $14.51 and its two-hundred day moving average price is $20.46. Denali Therapeutics has a one year low of $10.57 and a one year high of $33.33. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -5.96 and a beta of 1.49.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. Bank of America reduced their price objective on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Morgan Stanley initiated coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 price target on the stock. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. B. Riley reissued a "buy" rating and issued a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target for the company. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics has an average rating of "Buy" and a consensus target price of $37.57.
Get Our Latest Analysis on DNLI
About Denali Therapeutics
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
See Also
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
